Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Advocates are working to deliver medication directly to patients to combat this alarming decrease in care.
People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.
The three-drug combination cured most people who had experienced previous treatment failure.
ReLink programs treated 19% of people who were brought back into HCV care after being lost to follow-up.
Current guidelines recommend antiviral treatment regardless of alcohol use.
Two thirds of people who currently use drugs completed treatment, and most of those were cured.
People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.
Study findings suggest HCV-RNA-positive kidneys are not inferior in the direct-acting antiviral era.
People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.
However, people with liver cirrhosis remain at risk and should continue screening even after being cured.
The short treatment could make transplantation of organs from donors with HCV more safe, effective and economical.
Mavyret was associated with the most improvement in post-traumatic stress disorder symptoms.
Cure rate was three times as high for people who received treatment through a syringe service program.
However, rates of persistent HCV infection at age 5 were lower than previously assumed.
Left untreated, hepatitis C can lead to cirrhosis, liver cancer and the need for a liver transplant.
However, people who are not successfully treated may continue to experience declines in mental health.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.